Eli Lilly (LLY) stock rose as much as 10% in midday trading on Wednesday after the American drugmaker rolled out a strong sales outlook that touted the strength of its weight-loss portfolio and sent its market cap back near $1 trillion. The rally in Lilly also pressured shares of its main weight-loss rival, Danish drugmaker Novo Nordisk (NVO), for a second straight day. Novo stock fell as much as 6% in afternoon trade on Wednesday. Eli Lilly reported Wednesday morning that it expects 2026 revenue to gro ...